Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic
Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) The
SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic pruritus of
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time.
SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
Tranche 2 upsized by $7 million to provide enhanced financial runway to support Atento's restructuring following substantial interest from existing investorsParticipation in Tranche 2 reflects incremental support for
Delisting is contemplated by the previously announced comprehensive financial restructuring plan aimed at optimizing financial and operational efficiency and driving long-term growth. Delisting affects only the shares of
Atento enters into a restructuring support agreement with certain key financial stakeholders to obtain support for a comprehensive balance sheet restructuringAtento continues to work with additional financial
Atento agrees to term sheet with certain major financial stakeholders for at least $30 million of new financing in the near term and pathway to restructuring support agreement Term sheet provides for additional $79
